Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect

References

• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822.
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809.
   PubMed Web of Science ®Google Scholar
• McClung M, Recker R, Miller R, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41:122–128.
   PubMed Web of Science ®Google Scholar
• Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–795.
   PubMed Web of Science ®Google Scholar
• WHO (World Health Organization). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva, Switzerland: WHO. 1994.
   Google Scholar
• NOF (National Osteoporosis Foundation). Fast facts on osteoporosis. National Osteoporosis Foundation 2008a. Available at: http://www.nof.org/osteoporosis/diseasefacts.htm (accessed August 25, 2008).
   Google Scholar
• Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38(2 Suppl 1):S4–S9.
   Web of Science ®Google Scholar
• Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16:229–238.
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22:465–475.
   PubMed Web of Science ®Google Scholar
• Brenneman SK, Barrett-Connor E, Sajjan S, Markson LE, Siris ES. Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res. 2006;21:809–816.
   PubMed Web of Science ®Google Scholar
• USDHHS (US Department of Health and Human Services). Bone health and osteoporosis: a report of the surgeon general. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General. 2004. Available at: http://www.surgeongeneral.gov/library/bonehealth/Executive_Summary.html.
   Google Scholar
• Gabriel SE, Tosteson AN, Leibson CL, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int. 2002;13:323–330.
   PubMed Web of Science ®Google Scholar
• NOF (National Osteoporosis Foundation). Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008b.
   Google Scholar
• Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK: Printed by the University of Sheffield; 2007.
   Google Scholar
• Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate – a meta-analysis. JAMA. 1997;277:1159–1164.
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis – a randomized controlled trial. JAMA. 1999;282: 1344–1352.
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85:4118–4124.
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens R, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344: 333–340.
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005;165:346–347.
   PubMedGoogle Scholar
• Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479–1489.
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene – results from a 3-year randomized clinical trial. JAMA. 1999; 282:637–645.
   PubMed Web of Science ®Google Scholar
• Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872–881.
   PubMed Web of Science ®Google Scholar
• MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric. 2001;4:58–74.
   PubMedGoogle Scholar
• Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicologic Pathology. 2002;30:312–321.
   PubMed Web of Science ®Google Scholar
• Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004;32:426–438.
   PubMed Web of Science ®Google Scholar
• Tashjian AH Jr, Gagel RF. Teriparatide [human PTH(1–34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res. 2006;21:354–365.
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Center JR, Eisman JA. Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust. 2004;180(5 Suppl):S18–S22.
   Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from two US claims databases. Mayo Clin Proc. 2006;81:1013–1022.
   PubMed Web of Science ®Google Scholar
• Delmas PD, van de Langerijt L, Watts NB, et al. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res. 2005;20:557–563.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int. 2005;16:134–141.
   PubMed Web of Science ®Google Scholar
• Kamel HK. Secondary prevention of hip fractures among the hospitalized elderly: are we doing enough? J Clin Rheumatol. 2005;11:68–71.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21:1453–1460.
   PubMed Web of Science ®Google Scholar
• Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856–861.
   PubMed Web of Science ®Google Scholar
• Reginster JY, Rabenda V, NeuprezA. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006; 38(4 Suppl 1):S2–S6.
   Web of Science ®Google Scholar
• Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60:896–905.
   PubMed Web of Science ®Google Scholar
• McCombs JS, Thiebaud R, Laughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271–287.
   PubMed Web of Science ®Google Scholar
• Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231–236.
   PubMed Web of Science ®Google Scholar
• Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005;139:101–111.
   PubMed Web of Science ®Google Scholar
• Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–761.
   PubMed Web of Science ®Google Scholar
• Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc. 2008;139:32–40.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf. 2007;6:663–672.
   PubMed Web of Science ®Google Scholar
• Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168:826–831.
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008;336:813–816.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11:556–561.
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B, Tosteson AN, Melton LJ III, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19:449–458.
   PubMed Web of Science ®Google Scholar
• Tosteson AN, Melton LJ III, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int.2008;19:437–47.
   PubMed Web of Science ®Google Scholar